Toward the end of trading Wednesday, the Dow traded down 0.92% to 33,983.29 while the NASDAQ fell 0.68% to 13,977.59. The S&P also fell, dropping 0.74% to 4,215.21.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,486,910 cases with around 600,280 deaths. India confirmed a total of at least 29,633,100 cases and 379,570 deaths, while Brazil reported over 17,533,220 COVID-19 cases with 490,690 deaths. In total, there were at least 176,682,210 cases of COVID-19 worldwide with more than 3,823,780 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Financial shares rose 0.1% on Wednesday. Meanwhile, top gainers in the sector included The Duckhorn Portfolio, Inc. NAPA 2.92%, up 3%, and Vital Farms, Inc. VITL 2.37%, up 2%.
In trading on Wednesday, consumer staples shares fell 1.2%.
Top Headline
The Federal Reserve maintained its target fed funds rate range of between zero and 0.25%.
Eleven Fed members see no change to interest rates through at least 2022. Five members forecast rates will rise by 0.25% by the end of 2022 and two members forecast a 0.5% rise. All but five members now forecast at least one rate hike by the end of 2023.
Equities Trading UP
Kindred Biosciences, Inc. KIN 45.58% shares shot up 45% to $9.21 after Elanco announced an agreement to acquire the company for $9.25 per share.
Shares of Aprea Therapeutics, Inc. APRE 10.93% got a boost, shooting 21% to $5.88 after the company announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.
Forward Industries, Inc. FORD 15.75% shares were also up, gaining 11% to $3.0312 after the company announced a U.S. distribution agreement with Chipolo.
Equities Trading DOWN
Paratek Pharmaceuticals, Inc. PRTK 12.12% shares tumbled 12% to $8.99. Paratek Pharmaceuticals initiated Phase 2b trial evaluating Nuzyra (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease caused by Mycobacterium abscessus complex (MABc).
Shares of Inhibikase Therapeutics, Inc. IKT 27.14% were down 29% to $2.8701 after the company priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million.
Blue Apron Holdings, Inc. APRN 22.27% was down, falling 22% to $4.2950 after the company priced public offering of 4.706 million shares of Class A common stock at $4.25 per share.
Commodities
In commodity news, oil traded down 0.2% to $71.96, while gold traded down 0.8% to $1,842.40.
Silver traded down 0.5% Wednesday to $27.56 while copper rose 0.1% to $4.3380.
Euro zone
European shares closed mixed today. The eurozone’s STOXX 600 gained 0.23%, the Spanish Ibex Index fell 0.31% and the German DAX 30 fell 0.12%. Meanwhile, the London’s FTSE 100 gained 0.17%, French CAC 40 climbed 0.20% and Italy’s FTSE MIB rose 0.12%.
UK’s producer prices rose 4.6% year-on-year in May, while consumer price inflation rate increased to 2.1% year-over-year.
Economics
Housing starts rose 3.6% to an annualized rate of 1.572 million in May, while building permits fell 3.0% to a 1.681 million rate.
US import prices increased 1.1% in May, while prices for exports climbed 2.2%.
US crude-oil inventories dropped 7.4 million barrels last week, the Energy Information Administration said.
The Federal Reserve maintained its target fed funds rate range of between zero and 0.25%.
Benzinga does not provide investment advice. All rights reserved.
Recommended Content
Editors’ Picks
EUR/USD holds gains above 1.0700, as key US data loom
EUR/USD holds gains above 1.0700 in the European session on Thursday. Renewed US Dollar weakness offsets the risk-off market environment, supporting the pair ahead of the key US GDP and PCE inflation data.
GBP/USD extends recovery above 1.2500, awaits US GDP data
GBP/USD is catching a fresh bid wave, rising above 1.2500 in European trading on Thursday. The US Dollar resumes its corrective downside, as traders resort to repositioning ahead of the high-impact US advance GDP data for the first quarter.
Gold price edges higher amid weaker USD and softer risk tone, focus remains on US GDP
Gold price (XAU/USD) attracts some dip-buying in the vicinity of the $2,300 mark on Thursday and for now, seems to have snapped a three-day losing streak, though the upside potential seems limited.
XRP extends its decline, crypto experts comment on Ripple stablecoin and benefits for XRP Ledger
Ripple extends decline to $0.52 on Thursday, wipes out weekly gains. Crypto expert asks Ripple CTO how the stablecoin will benefit the XRP Ledger and native token XRP.
US Q1 GDP Preview: Economic growth set to remain firm in, albeit easing from Q4
The United States Gross Domestic Product (GDP) is seen expanding at an annualized rate of 2.5% in Q1. The current resilience of the US economy bolsters the case for a soft landing.